2011
P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11?
Lannin D, Killelea B, Grube B, Horowitz N, Chagpar A. P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11? Cancer Research 2011, 71: p3-07-26-p3-07-26. DOI: 10.1158/0008-5472.sabcs11-p3-07-26.Peer-Reviewed Original ResearchPositive sentinel nodesSentinel node biopsySentinel nodesPositive nodesAxillary dissectionNode biopsyLower axillary recurrence ratePositive sentinel lymph nodesAxillary recurrence rateNode-positive patientsNeo-adjuvant chemotherapyPercentage of patientsNegative sentinel nodesBreast cancer patientsSentinel lymph nodesEligibility requirementsLumpectomy patientsZ11 trialT4 tumorsPositive patientsLymph nodesRecurrence ratePatient populationCancer patientsInstitutional database
2009
Optimal timing of radioactive tracer for sentinel node biopsy in breast cancer patients
Reuter N, Bower M, Scoggins C, Martin R, McMasters K, Chagpar A. Optimal timing of radioactive tracer for sentinel node biopsy in breast cancer patients. Journal Of Clinical Oncology 2009, 27: 611-611. DOI: 10.1200/jco.2009.27.15_suppl.611.Peer-Reviewed Original ResearchSentinel node biopsyBreast cancer patientsNode biopsySentinel nodesCancer patientsFalse negative rateOptimal timingFN rateSN identification rateMean tumor sizeProspective multicenter studyOverall false-negative rateNon-significant trendCohort of interestMulticenter studyTumor sizeMean ageSulfur colloidBreast cancerSN identificationPatientsInvasive meansNegative rateSignificant financial relationshipHot nodes